Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379584 | 0.95 | ADRB2 (0.35) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL1361234 | 0.95 | ADRB2 (0.35) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL12544435 | 0.93 | ADRB2 (0.33) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL9781144 | 0.91 | DNM1 (0.36) | TSHR | |
| SCHEMBL11707211 | 0.89 | ADRB2 (0.31) | ADRB2ADRB1ADRB3 | |
| SCHEMBL7548413 | 0.88 | DNM1 (0.33) | TSHR | |
| SCHEMBL25178012 | 0.87 | TSHR (0.40) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL25178057 | 0.87 | TSHR (0.40) | ADRB2ADRB1ADRB3CYP3A4TSHR | |
| SCHEMBL11405161 | 0.86 | DNM1 (0.36) | TSHR | |
| SCHEMBL11306849 | 0.86 | DNM1 (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570771-B2 | Curing catalyst used for curing of polymer, production method for said curing catalyst, mositure-curable composition, and production method for cured product | NITTO KASEI CO., LTD. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4682204-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2026-01-21 | — | — | EP | disclosed |
| EP-4656672-A1 | METHOD FOR PRODUCING CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4174052-B1 | CURING CATALYST USED FOR CURING OF POLYMER, PRODUCTION METHOD FOR SAID CURING CATALYST, MOISTURE-CURABLE COMPOSITION, AND PRODUCTION METHOD FOR CURED PRODUCT | NITTO KASEI CO LTD (JP) | 2025-11-26 | — | — | EP | disclosed |
| EP-4596622-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4567075-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025111365-A1 | METHOD OF PREPARING A MOISTURE CURABLE RESIN COMPOSITION WITH A NON-TIN CATALYST | KANEKA AMERICAS HOLDING, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-12312464-B2 | Curing catalyst used for curing of polymer, moisture curable composition, and method for producing cured product | NITTO KASEI CO., LTD. (JP) | 2025-05-27 | — | — | US | disclosed |
| US-12285742-B2 | Curing catalyst used for curing of polymer, production method for said curing catalyst, moisture-curable composition, and production method for cured article | NITTO KASEI CO., LTD. (JP) | 2025-04-29 | — | — | US | disclosed |
| EP-4067337-B1 | CURING CATALYST USED FOR CURING OF POLYMER, MOISTURE CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | NITTO KASEI CO LTD (JP) | 2025-04-23 | — | — | EP | disclosed |
| WO-2022004510-A1 | CURING CATALYST USED FOR CURING OF POLYMER, PRODUCTION METHOD FOR SAID CURING CATALYST, MOISTURE-CURABLE COMPOSITION, AND PRODUCTION METHOD FOR CURED PRODUCT | 日東化成株式会社 | 2022-01-06 | — | — | WO | disclosed |
| WO-2021106943-A1 | CURING CATALYST USED FOR CURING OF POLYMER, PRODUCTION METHOD FOR SAID CURING CATALYST, MOISTURE-CURABLE COMPOSITION, AND PRODUCTION METHOD FOR CURED ARTICLE | 日東化成株式会社 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021106942-A1 | CURING CATALYST USED FOR CURING OF POLYMER, MOISTURE CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | 日東化成株式会社 | 2021-06-03 | — | — | WO | disclosed |
| US-8563675-B2 | Curable compositions composed of silanes with two hydrolyzable groups | HENKEL AG & CO. KGAA (DE) | 2013-10-22 | — | — | US | disclosed |
| US-8450411-B2 | Curable composition having a silane-modified reactive thinner | HENKEL AG & CO. KGAA (DE) | 2013-05-28 | — | — | US | disclosed |
| US-20120108730-A1 | CURABLE COMPOSITION HAVING A SILANE-MODIFIED REACTIVE THINNER | HENKEL AG & CO. KGAA (DE) | 2012-05-03 | — | — | US | disclosed |
| US-8067508-B2 | Compositions consisting of partially silyl-terminated polymers | HENKEL AG & CO. KGAA (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20100204387-A1 | CURABLE COMPOSITIONS COMPOSED OF SILANES WITH TWO HYDROLYZABLE GROUPS | HENKEL AG & CO. KGAA (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100143712-A1 | SILANE-CROSSLINKING ADHESIVE OR SEALANT COMPRISING N-SILYLALKYLAMIDES AND USE THEREOF | HENKEL AG & CO. KGAA (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100081757-A1 | COMPOSITIONS CONSISTING OF PARTIALLY SILYL-TERMINATED POLYMERS | HENKEL AG & CO. KGAA (DE) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570771-B2 | Curing catalyst used for curing of polymer, production method for said curing catalyst, mositure-curable composition, and production method for cured product | RPS6KB1, RPS6KA1, RPS6KB2 | ADRB2 1818/4885ADRB1 1801/4885ADRB3 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.